06:20 AM EDT, 06/23/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Sunday that participants with obesity in a phase 3 study met its primary endpoint of greater weight loss with a higher 7.2mg dose of Wegovy.

Patients showed mean weight loss of 20.7%, with a third of participants losing 25% or more, compared with 17.4% for those taking the 2.4mg dose, and 2.4% for the placebo at 72 weeks, the company said.

According to the company, 93.2% of participants taking the 7.2mg dose showed a weight loss of 5% or more after 72 weeks, compared with 92.5% for those taking 2.4 milligrams, and only 35.7% for those taking placebo.

Novo Nordisk ( NVO ) said it expects to file the higher Wegovy dose for a label update in the European Union in H2, followed by regulatory submissions in other markets.